Nasdaq

AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID

Growing body of data supports Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for a Phase 2 study of Ampligen for the treatment of Post-COVID conditions ...
Seeking Alpha

AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer

OCALA, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (AIM) (NYSE American: AIM) (“AIM”), an immuno-pharma company focused on the research and development of therapeutics to treat ...
Nasdaq

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

OCALA, Fla., Sept. 19, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced positive preliminary data from the Phase 1b/2 study (“DURIPANC”) evaluating the ...
Hosted on MSN

AIM ImmunoTech reports Ampligen combo trial data for pancreatic cancer

AIM ImmunoTech has announced encouraging data from the ongoing Phase II trial of its Ampligen (rintatolimod) drug plus AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer subjects with ...